Advertisement

Digestive Diseases and Sciences

, Volume 35, Issue 9, pp 1153–1161 | Cite as

Dopamine in gastrointestinal disease

  • Gary B. Glavin
  • Sandor Szabo
Review Article

Abstract

Dopamine is an important enteric neuromodulator. Herein we review the data that support a role for dopaminergic involvement in experimental duodenal and gastric ulceration; gastric, pancreatic, and duodenal secretion; gastrointestinal motility; and gastric and intestinal submucosal blood flow regulation. There also is support for a role for dopamine and dopamimetic agents in the treatment of certain experimental gastrointestinal diseases because some highly selective dopamine agonists are gastroprotective when given either parenterally or centrally. Based upon these observations, we suggest that dopamine is a key element of the “brain-gut axis” and represents a potentially important target for pharmacotherapeutic exploitation.

Key words

dopamine ulcer gastric acid secretion stomach duodenum motility dopamine DA1/DA2 receptors 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Brooks F: The pathophysiology of peptic ulcer: An overview.In Peptic Ulcer Disease. F Brooks, S Cohen, R Soloway (eds). New York, Churchill Livingstone, 1985, pp 45–149Google Scholar
  2. 2.
    Szabo S: Biology of disease-pathogenesis of duodenal ulcer disease. Lab Invest 51:121–147, 1983Google Scholar
  3. 3.
    Szabo S, Bynum T: Alternatives to the acid-oriented approach to ulcer disease: Does “cytoprotection” exist in man? Scand J Gastroenterol 23:1–6, 1988PubMedGoogle Scholar
  4. 4.
    Szabo S, Szelenyi I: “Cytoprotection” in gastrointestinal pharmacology. Trends Pharmacol Sci 8:149–154, 1987Google Scholar
  5. 5.
    Tarnawski A, Hollander D, Gergely H: The mechanism of protective, therapeutic and prophylactic actions of sucral-fate. Scand J Gastroenterol 22:7–13, 1987Google Scholar
  6. 6.
    Sewing K-F, Beil W: Experimental studies with proton pump inhibitors.In Advances in Drug Therapy of Gastrointestinal Ulceration. A Garner, B Whittle (eds), New York, Wiley/Liss, 1989, pp 53–66Google Scholar
  7. 7.
    McCloy R: Mechanisms of action of non-antisecretory antiulcer drugs.In Advances in Drug Therapy of Gastrointestinal Ulceration. A Garner, B Whittle (eds). New York, Wiley/Liss, 1989, pp 121–130Google Scholar
  8. 8.
    Tache Y: Central nervous system regulation of gastric acid secretion.In Physiology of the Gastrointestinal Tract, Vol 2. L Johnson (ed). New York, Raven Press, 1987, pp 911–930Google Scholar
  9. 9.
    Willems J, Buylaert W, Lefebvre R, Bogaert M: Neuronal dopamine receptors on autonomic ganglia and sympathetic nerves and dopamine receptors in the gastrointestinal system. Pharmacol Rev 37:165–216, 1985PubMedGoogle Scholar
  10. 10.
    Hernandez D, Mason G: Involvement of dopamine and dopamine receptors in stress gastric ulceration.In Ulcer Disease: New Aspects of Pathogenesis and Pharmacology. S Szabo, C Pfeiffer (eds). Boca Raton, CRC Press, 1989, pp 207–215Google Scholar
  11. 11.
    Strang R: The association of gastro-duodenal ulceration and Parkinson's disease. Med J Austral 1:842–843, 1965Google Scholar
  12. 12.
    Szabo S: Dopamine disorder in duodenal ulceration. Lancet 2:880–882, 1979PubMedGoogle Scholar
  13. 13.
    Szabo S, Pihan G: Development and significance of cysteamine and propionitrile models of duodenal ulcer. Chronobiol Int 4:31–42, 1987PubMedGoogle Scholar
  14. 14.
    Lauterbach H, Mattes P: Effect of dopamine in stress ulcer of rats. Eur Surg Res 9:258–263, 1977PubMedGoogle Scholar
  15. 15.
    Caldara R, Ferrari C, Romussi M, Bierti L, Ganoini S, Curtarelli G: Effect of dopamine infusion on gastric and pancreatic secretion and on gastrin release in man. Gut 19:724–728, 1978PubMedGoogle Scholar
  16. 16.
    Valenzuela J, DeFilippi C, Diaz G, Navia E, Merino Y: Effect of dopamine on human gastric and pancreatic secretion. Gastroenterol 76:323–326, 1979PubMedGoogle Scholar
  17. 17.
    Szabo S, Horner H, Gallagher G, Silver E, Hollenberg N, Reichlin S: Pathogenesis of duodenal ulcer induced by cysteamine and propionitrile in the rat. Fed Proc 39:326, 1980Google Scholar
  18. 18.
    Horner H, Szabo S: Central and peripheral dopamine and noradrenaline in the pathogenesis of cysteamine-induced duodenal ulcer disease. Gastroenterol 78:1183, 1980Google Scholar
  19. 19.
    Horner H, Szabo S: Differential effect of changing central and peripheral catecholamine levels in cysteamine-induced duodenal ulcer in the rat. Life Sci 29:2437–2443, 1981PubMedGoogle Scholar
  20. 20.
    Szabo S, Horner H, Maull H, Schnoor J, Chiueh C, Palkovits M: Biochemical changes in tissue catecholamines and serotonin in duodenal ulceration caused by cysteamine or propionitrile in the rat. J Pharmacol Exp Ther 240:871–878, 1987PubMedGoogle Scholar
  21. 21.
    Oishi T, Szabo S: Effect of tyrosine administration on duodenal ulcer induced by cysteamine in the rat. J Pharmacol Exp Ther 240:879–882, 1987PubMedGoogle Scholar
  22. 22.
    Szabo S, Neumeyer J: Dopamine agonists and antagonists in duodenal ulcer disease.In Dopamine Receptors. C Kaiser, J Kebabian (eds). Washington DC, American Chemical Society, 1983, pp 175–196Google Scholar
  23. 23.
    Neumeyer J, Szabo S: (-)-10,11-methylenedioxy-N-propylnorapomorphine, an orally effective dopamine agonist and duodenal antiulcerogen in the rat. Eur J Pharmacol 88:273–274, 1983PubMedGoogle Scholar
  24. 24.
    Gallagher G, Brown A, Szabo S: Effect of dopamine-related drugs on duodenal ulcer induced by cysteamine or propionitrile: Prevention and aggravation may not be mediated by gastrointestinal secretory changes in the rat. J Pharmacol Exp Ther 240:883–889, 1987PubMedGoogle Scholar
  25. 25.
    Langsten J, Ballard P, Tetrud J, Irwin I: Chronic Parkinsonism in humans due to a product in meperidine-analog synthesis. Science 219:979–980, 1983PubMedGoogle Scholar
  26. 26.
    Heikkila R, Hess A, Duvoisin R: Dopaminergic neurotoxicity by 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice. Science 224:1451–1453, 1984PubMedGoogle Scholar
  27. 27.
    Nicklas W, Vyas I, Heikkila R: Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenylpyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Life Sci 36:2503–2508, 1985PubMedGoogle Scholar
  28. 28.
    Cohen G: Oxy-radical toxicity in catecholamine neurons. Neurotoxicology 5:77–82, 1984PubMedGoogle Scholar
  29. 29.
    Szabo S, Brown A, Schnoor J: Duodenal ulcer induction by a chemical that also causes Parkinson's disease. Fed Proc 43:945, 1984Google Scholar
  30. 30.
    Szabo S, Brown A, Pihan G, Dali H, Neumeyer J: Duodenal ulcer by MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine). Proc Soc Exp Biol Med 180:567–571, 1985PubMedGoogle Scholar
  31. 31.
    Fields J, Dali H, Neumeyer J, Szabo S: Duodenal ulcers induced by MPTP may be caused by nigrostriatal lesion.In MPTP: A Neurotoxin Producing a Parkinsonian Syndrome. S Markey, N Castagnoli, A Trevor, I Kopin (eds). New York Academic Press, 1986, pp 385–392Google Scholar
  32. 32.
    Szabo S, Cho C: From cysteamine to MPTP: Structure-activity studies with duodenal ulcerogens. Toxicol Pathol 16:205–212, 1988PubMedGoogle Scholar
  33. 33.
    Pihan G, Szabo S: The dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is a new duodenal ulcerogen in the rat.In Ulcer Disease: New Aspects of Pathogenesis and Pharmacology. S Szabo, C Pfeiffer (eds). Boca Raton, CRC Press, 1989, pp 297–304Google Scholar
  34. 34.
    Glavin G: Central dopamine involvement in stress-induced gastric pathology. Clin Neuropharmacol 1990 (in press)Google Scholar
  35. 35.
    Szabo S, Sandrock A, Nafradi J, Maull A, Gallagher G, Blyzniuk A: Dopamine and dopamine receptors in the gut: Their possible role in duodenal ulceration.In Advances in Dopamine Research, Vol 37. M Kohsaka, T Shohmori, Y Tsukada, G Woodruff (eds). New York, Pergamon, 1982, pp 165–170Google Scholar
  36. 36.
    Sandrock A: Identification and binding properties of dopamine receptors in the rat gut: Possible role in experimental duodenal ulcerogenesis. Gastroenterology 80:1362, 1981Google Scholar
  37. 37.
    Hernandez D, Walker C, Valenzuela J, Mason G: Increased dopamine receptor binding in duodenal mucosa of duodenal ulcer patients. Dig Dis Sci 34:543–547, 1989PubMedGoogle Scholar
  38. 38.
    Hernandez D, Mason G, Valenzuela J: Dopamine binding sites in human gastrointestinal mucosa. Gastroenterol 92:1433, 1987Google Scholar
  39. 39.
    Sikiric P, Rotkvic I, Mise S, Petek M, Rucman R, Seiwerth S: Dopamine agonists and H2 receptors antagonists in duodenal ulcer treatment—A comparative blind study. Dig Dis Sci 34:1320, 1989Google Scholar
  40. 40.
    Fields J: Aging and a novel neurotoxin, MPTP (1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine) elicit deficits in brain dopamine tracts and increases in duodenal ulcers. Dig Dis Sci 30:374, 1985Google Scholar
  41. 41.
    Hernandez D, Orlando R, Adcock J, Patrick K, Nemeroff C, Prange A: Gastric cytoprotection by dopamine agonists. Clin Res 31:683A, 1983Google Scholar
  42. 42.
    Hernandez D, Adcock J, Orlando R, Patrick K, Nemeroff C, Prange A: Prevention of stress-induced gastric ulcers by dopamine agonists in the rat. Life Sci 35:2453–2458, 1984PubMedGoogle Scholar
  43. 43.
    Sikiric P, Geber J, Suchanek E, Ivanovic D, Gjuris V, Aleksic J, Reic P, Marovic A: The role of dopamine in the formation of gastric ulcers in rats. Eur J Pharmacol 112:127–128, 1985PubMedGoogle Scholar
  44. 44.
    Parmar N, Tariq M, Ageel A: Effect of bromocriptine, a dopamine receptor agonist, on the experimentally induced gastric ulcers in albino rats. Life Sci 35:2035–2039, 1984PubMedGoogle Scholar
  45. 45.
    Groisman S, Karevina T, Khokholya V: Role of dopamine receptors in the mechanism of stress injuries of the stomach. Bull Exp Med Biol 97:67–70, 1984Google Scholar
  46. 46.
    Zavodskaya I, Moreva E, Migas E, Zabrodin O: Pharmacological analysis of the norepinephrine role in the experimental gastric ulceration. Biogenic Amines 2:235–241, 1985Google Scholar
  47. 47.
    Sikiric P, Geber J, Ivanovic D, Suchanek E, Gjuris V, Mise S, Reic P, Marovik A: The role of dopamine on stress gastric ulcer. Yugoslav Physiol Pharmacol Acta 21:345–346, 1985Google Scholar
  48. 48.
    Glavin G, Dugani A, Pinsky C:l-deprenyl attenuates stress ulcer formation in rats. Neurosci Lett 70:379–381, 1986PubMedGoogle Scholar
  49. 49.
    Hernandez D, Stanley D, Melvin J, Prange A: Role of brain neurotransmitters on neurotensin-induced gastric cytoprotection. Pharmacol Biochem Behav 22:509–513, 1985PubMedGoogle Scholar
  50. 50.
    Pare W, Glavin G: Restraint stress in biomedical research: A review. Neurosci Biobehav Rev 10:339–370, 1986PubMedGoogle Scholar
  51. 51.
    Sikiric P, Rotkvik I, Mise S, Krizanac S, Suchanek E, Petek M, Gjuris V, Geber J, Tucan-Foretic M, Udovicic I, Anic T, Balen I: The influence of dopamine agonists and antagonists on gastric lesions in mice. Eur J Pharmacol 144:237–239, 1987PubMedGoogle Scholar
  52. 52.
    Sikiric P, Rotkvic I, Mise S, Krizanac S, Gjuris V, Jukic J, Suchanek E, Petek M, Udovicic I, Kalogjera L, Geber J, Tucan-Foretic M, Duvnjak M, Phillipp M, Balen I, Anic T: The influence of dopamine agonists and antagonists on ihdomethacin lesions in stomach and small intestine in rats. Eur J Pharmacol 158:61–67, 1988PubMedGoogle Scholar
  53. 53.
    Sikiric P, Geber J, Ivanovic D, Suchanek E, Gjuris V, Tucan-Foretic M, Mise S, Cvitanovic B, Rotkvic I: Dopamine antagonists induce gastric lesions in rats. Eur J Pharmacol 131:105–109, 1986PubMedGoogle Scholar
  54. 54.
    MacNaughton W, Wallace J: A role for dopamine as an endogenous protective factor in the rat stomach. Gastroenterology 96:972–980, 1989PubMedGoogle Scholar
  55. 55.
    Chaudhury T, Robert A: Prevention by mild irritants of gastric necrosis produced in rats by sodium taurocholate. Dig Dis Sci 25:830–836, 1980PubMedGoogle Scholar
  56. 56.
    Robert A, Nezamis J, Lancaster C, Davis J, Field S, Hanchar A: Mild irritants prevent gastric necrosis through “adaptive cytoprotection” mediated by prostaglandins. Am J Physiol 245:G113-G121, 1983PubMedGoogle Scholar
  57. 57.
    MacNaughton W, Williamson T, Morris G: Adaptive cytoprotection is truly “cytoprotective,” and may not depend upon elevated levels of prostaglandin synthesis. Can J Physiol Pharmacol 66:1075–1081, 1988PubMedGoogle Scholar
  58. 58.
    Glavin G, Dugani A: Effects of dopamine agonists and antagonists on gastric acid secretion and stress responses in rats. Life Sci 41:1397–1408, 1987PubMedGoogle Scholar
  59. 59.
    Ray A, Henke P, Sullivan R: The central amygdala and immobilization stress-induced gastric pathology in rats: Neurotensin and dopamine. Brain Res 409:398–402, 1987PubMedGoogle Scholar
  60. 60.
    Ray A, Henke P, Sullivan R: Effects of intra-amygdalar dopamine agonists and antagonists on gastric stress lesions in rats. Neurosci Lett 84:302–306, 1988PubMedGoogle Scholar
  61. 61.
    Ray A, Henke P, Sullivan R: Central dopamine systems and gastric stress pathology in rats. Physiol Behav 42:359–364, 1988PubMedGoogle Scholar
  62. 62.
    Lindvall O, Bjorklund A: Anatomy of the dopaminergic neuron systems of the rat brain.In Advances in Biochemical Psychopharmacology. P Roberts (ed). New York, Raven Press, 1978, pp 1–23Google Scholar
  63. 63.
    Hernandez D: Isolation and purification of the dopamine receptor from rat gastric muscle. Gastroenterology 96:A206, 1989Google Scholar
  64. 64.
    Hernandez D, Mason G, Walker C, Valenzuela J: Dopamine receptors in human gastrointestinal mucosa. Life Sci 41:2717–2723, 1987PubMedGoogle Scholar
  65. 65.
    Glavin G: Activity of selective dopamine DA1 and DA2 agonists and antagonists on experimental gastric lesions and gastric acid secretion. J Pharmacol Exp Ther 251:726–730, 1989PubMedGoogle Scholar
  66. 66.
    Caldara R, Ferrari C, Romussi M, Bierti L, Gandini S, Curtarelli G: Effect of dopamine infusion on gastric and pancreatic secretion and on gastrin release in man. Gut 19:724–728, 1978PubMedGoogle Scholar
  67. 67.
    Caldara R, Ferrari C, Romussi M, Paracchi A: Effect of bromocriptine administration on gastric acid and gastrin secretion in man. J Endocrinol Invest 2:45–49, 1978Google Scholar
  68. 68.
    Caldara R, Ferrari C, Barbieri C, Romussi M: Effect of four dopamine receptor antagonists on gastrin secretion in healthy subjects. Scand J Gastroenterol 15:481–484, 1980PubMedGoogle Scholar
  69. 69.
    Caldara R, Grimaldi M, Barbieri C, Ferarri C: Serum gastrin concentrations in patients with rheumatoid arthritis: effect of long-term immunosuppressive or antidopaminergic treatment. Horm Metab Res 13:615–617, 1981PubMedGoogle Scholar
  70. 70.
    Costall B, Naylor R, Tan C: Mechanism of action of apomorphine on rat gastric secretion. Eur J Pharmacol 116:279–285, 1985PubMedGoogle Scholar
  71. 71.
    Goiny M, Uvnas-Moberg K: Effects of dopamine receptor antagonists on gastrin and vomiting responses to apomorphine. Arch Pharmacol 336:16–19, 1987Google Scholar
  72. 72.
    Caldara R, Barbieri C: The dopaminergic system in the regulation of gastric acid secretion and gastrin release: Experimental data and therapeutic implications.In New Pharmacology of Ulcer Disease. S Szabo, G Mozsik (eds). New York, Elsevier, 1987, pp 232–243Google Scholar
  73. 73.
    Pappas T, Tache Y, Debas H: Opposing central and peripheral actions of brain-gut peptides: A basis for regulation of gastric function. Surgery 98:183–190, 1985PubMedGoogle Scholar
  74. 74.
    Costall B, Naylor R, Tan C: A central site of dopamine agonist action to modify gastric secretion in the rat. Eur J Pharmacol 117:61–69, 1985PubMedGoogle Scholar
  75. 75.
    Zhang L, Kauffman G: Central dopamine-2 (DA2) receptors may mediate the antisecretory effect of centrally administered neurotensin. Gastroenterology 92:1709, 1987Google Scholar
  76. 76.
    Szabo S, Moriga M: Neuropeptides and duodenal ulcers: The cysteamine story.In Neuropeptides and Stress. Y Tache, J Morley, M Brown (eds). New York, Springer-Verlag, 1989, pp 158–174Google Scholar
  77. 77.
    Pihan G, Dupuy D, Brown A, Szabo S: Duodenal hypermotility impairs acid neutralization in experimental duodenal ulceration. Gastroenterology 86:1210, 1984Google Scholar
  78. 78.
    Schuurkes J, Van Nueten J: Is dopamine an inhibitory modulator of gastrointestinal motility? Scand J Gastroenterol 16:33–36, 1981PubMedGoogle Scholar
  79. 79.
    Ormsbee H: Dopamine agonists/antagonists in the treatment of gastrointestinal diseases.In Dopamine Receptor Agonists. G Poste, S Crooke (eds). New York, Plenum, 1984, pp 333–353Google Scholar
  80. 80.
    Boselli C, Lucchelli A, Grana E: Receptors involved in the dopamine-induced relaxation of the isolated rat ileum. Pharmacol Res Commun 19:955–956, 1987Google Scholar
  81. 81.
    Hyeok Y, Sim S, Choi H, Kim M: Effect of dopamine on electrical activity of isolated stomach muscle in cats. Dig Dis Sci 34:548–552, 1989PubMedGoogle Scholar
  82. 82.
    Takeuchi K, Nishiwaki H, Okabe S: Effects of dopamine on gastric mucosal lesions induced by ethanol in rats: Possible involvement of antigastric motor activity mediated with alpha2-adrenoceptors. Dig Dis Sci 33:1560–1568, 1988PubMedGoogle Scholar
  83. 83.
    Dhasmana K, Banerjee A, Zhu Y, Erdmann W, Parmar S, Salzman S: Role of dopamine receptors in gastrointestinal motility. Res Commun Chem Pathol Pharmacol 64:485–488, 1989PubMedGoogle Scholar
  84. 84.
    Wiley J, Owyang C: Dopaminergic modulation of rectosigmoid motility: Action of domperidone. J Pharmacol Exp Ther 242:548–551, 1987PubMedGoogle Scholar
  85. 85.
    Kullman R, Breull W, Reinsberg J, Wassermann K, Konopatzki A: Dopamine produces vasodilation in specific regions and layers of the rabbit gastrointestinal tract. Life Sci 32:2115–2122, 1983PubMedGoogle Scholar
  86. 86.
    Kullmann R, Breull W, Wassermann K, Konopatzki A: Blood flow redistribution by dopamine in the feline gastrointestinal tract. Arch Pharmacol 323:145–148, 1983Google Scholar
  87. 87.
    Guth P, Leung F: Physiology of the gastric circulation.In Physiology of the Gastrointestinal Tract. L Johnson (ed). New York, Raven Press, 1987, pp 1031–1053Google Scholar
  88. 88.
    Sikiric P, Rotkvic I, Mise S, Krizanac S, Gjuris V, Jagic V, Suchanek E, Petek M, Udovicic I, Geber J, Tucan-Foretic M, Cvitanovic B, Ivanovic D, Marovic A: The influence of dopamine receptor agonists and an antagonist on acute pancreatitis is rats. Eur J Pharmacol 147:321–326, 1988PubMedGoogle Scholar
  89. 89.
    Xue B, Hernandez D: Effect of dopamine on amylase secretion from guinea pig pancreatic acinar cellsin vitro. Neurosci Lett 45:311–317, 1989Google Scholar

Copyright information

© Plenum Publishing Corporation 1990

Authors and Affiliations

  • Gary B. Glavin
    • 1
    • 2
  • Sandor Szabo
    • 1
    • 2
  1. 1.Department of Pharmacology and Therapeutics and Department of Surgery, Faculty of MedicineUniversity of ManitobaWinnipegCanada
  2. 2.Departments of PathologyBrigham and Women's Hospital, and Harvard Medical SchoolBoston

Personalised recommendations